N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

Sponsor: Seoul National University Hospital • ClinicalTrials.gov ID: NCT06977594

Registry updated: 2026-10-07
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: \- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: * Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.

Interventions

  • Proactive immune tolerance induction (Other)
    Proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles
  • Standard Treatment (Other)
    Standard treatment throughout all chemotherapy cycles
  • Paclitaxel and carboplatin (Drug)
    A chemotherapy regimen for gynecologic cancers.
  • Standard premedication (20 mg) (Drug)
    Premedication includes 20 mg of dexamethasone.
  • Reduced premedication (10 mg) (Drug)
    Premedication includes 20 mg of dexamethasone.
  • Reduced premedication (5 mg) (Drug)
    Premedication includes 5 mg of dexamethasone.

Eligibility criteria

Inclusion Criteria: * Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies. * Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin. * Patients who are able to read and voluntarily provide written informed consent. * Aged 19 years or older. Exclusion Criteria: * Patients who do not wish to participate in this study voluntarily. * Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.

Conditions

Ovarian Cancer Endometrial Cancer Cervical Cancer

Locations

  • Seoul National University Hospital — Seoul, South Korea
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record